Zosano Pharma Corp Deferred Tax Assets, in Process Research and Development
Zosano Pharma Corp had Deferred Tax Assets, in Process Research and Development of $4.76 million as of 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2022-03-17
- 2021-12-31: Deferred Tax Assets, in Process Research and Development $4.76M.
- 2020-12-31: Deferred Tax Assets, in Process Research and Development $4.15M.
- 2019-12-31: Deferred Tax Assets, in Process Research and Development $4.81M.
- 2018-12-31: Deferred Tax Assets, in Process Research and Development $3.66M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2021-12-31 | $4.76M 10-K · filed 2022-03-17 |
| 2020-12-31 | $4.15M 10-K · filed 2022-03-17 |
| 2019-12-31 | $4.81M 10-K · filed 2021-03-11 |
| 2018-12-31 | $3.66M 10-K · filed 2020-03-13 |
| 2017-12-31 | $3.25M 10-K · filed 2019-03-25 |
| 2016-12-31 | $2.62M 10-K · filed 2018-03-12 |
| 2015-12-31 | $5.25M 10-K · filed 2017-03-01 |
| 2014-12-31 | $4.67M 10-K · filed 2016-03-29 |